J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa
ZacksThe approval of J&J’s (JNJ) Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma is based on data from the phase III THOR study.
The approval of J&J’s (JNJ) Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma is based on data from the phase III THOR study.